Breast milk is superior in nutrition, It provides resistance against infections and allergies, It is naturally sterile. Despite all the advantages of breastfeeding some mothers choose to pause the breastfeeding in fear of harmful effects of medicines passing in breast milk. Are you wondering about breastfeeding and using Pravastatin Sodium | Mckesson Corporation Dba Rx Pak ? Know what is Pravastatin Sodium | Mckesson Corporation Dba Rx Pak and how it can affect your breast milk and whether Pravastatin Sodium | Mckesson Corporation Dba Rx Pak is safe for your kid or not.
What is Pravastatin Sodium | Mckesson Corporation Dba Rx Pak used for?
Pravastatin sodium tablet, USP is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. (1.1) Reduce the risk of total mortality by reducing coronary death, MI, revascularization, stroke/TIA, and the progression of coronary atherosclerosis in patients with clinically evident CHD. (1.1) Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. (1.2) Reduce elevated serum TG levels in patients with hypertriglyceridemia. (1.2) Treat patients with primary dysbetalipoproteinemia who are not responding to diet. (1.2) Treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. (1.2) Limitations of use: Pravastatin sodium tablet, USP has not been studied in Fredrickson Types I and V dyslipidemias. (1.3) Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Prevention of Cardiovascular Disease In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), pravastatin sodium tablet, USP is indicated to: reduce the risk of myocardial infarction (MI). reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. In patients with clinically evident CHD, pravastatin sodium tablet is indicated to: reduce the risk of total mortality by reducing coronary death. reduce the risk of MI. reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of stroke and stroke/transient ischemic attack (TIA). slow the progression of coronary atherosclerosis. 1.2 Hyperlipidemia Pravastatin sodium tablet is indicated: as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglyceride (TG) levels and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb).1 as an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV). for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. as an adjunct to diet and lifestyle modification for treatment of heterozygous familial hypercholesterolemia (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors are present in the patient. 1.3 Limitations of Use Pravastatin sodium has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V).
Is using Pravastatin Sodium | Mckesson Corporation Dba Rx Pak unsafe in breastfeeding? Can there be bad consequences for baby if I use it while breastfeeding?
As Pravastatin Sodium | Mckesson Corporation Dba Rx Pak is made of only Pravastatin sodium, and Pravastatin sodium is unsafe to use in breastfeeding we can safely reach on conclusion that Pravastatin Sodium | Mckesson Corporation Dba Rx Pak is also unsafe to use while breastfeeding. Below is detailed analysis of Pravastatin sodium and Pravastatin Sodium | Mckesson Corporation Dba Rx Pak during location. We recommend you to go through provided detailed analysis as below take decision accordingly. We also recommend you talk to your health care provider before making final decision.
Statement of Manufacturer/Labeler about breastfeeding usage
4.4 Lactation Pravastatin is present in human milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require pravastatin sodium treatment should not breastfeed their infants [see Use in Specific Populations (8.2)].
8.2 Lactation Risk Summary Pravastatin use is contraindicated during breastfeeding [see Contraindications (4.4)]. Based on one lactation study in published literature, pravastatin is present in human milk. There is no available information on the effects of the drug on the breastfed infant or the effects of the drug on milk production. Because of the potential for serious adverse reactions in a breastfed infant, advise patients that breastfeeding is not recommended during treatment with pravastatin sodium.
Pravastatin Sodium | Mckesson Corporation Dba Rx Pak Breastfeeding Analsys
Pravastatin sodium while Breastfeeding Unsafe
CAS Number: 81093-37-0
Statin drugs do its action by inhibiting cholesterol synthesis. On latest update relevant data on breastfeeding was not found. Its high plasma protein binding makes excretion into breast milk unlikely. Ability to alter fat composition of breast milk is unknown which is important since infants are in need of high cholesterol intake for adequate brain development, cell membrane building and hormone and vitamin synthesis. Avoid taking it at least while exclusive breastfeeding. Atorvastatin is possibly the safest statin drug because a higher molecular weight that lowers excretion into breast milk even more extensively. For Pravastatin a minimal excretion has been reported. Simvastatin has a lowest oral bioavailability. Avoiding drug treatment for cholesterol as long as breastfeeding is desired would probably not harm long term result of disease. Continuing with a low fat containing diet is recommended.
Pravastatin Sodium | Mckesson Corporation Dba Rx Pak Breastfeeding Analsys - 2
Pravastatin sodium while Breastfeeding
CAS Number: 81093-37-0
Levels of pravastatin in milk are low, but no relevant published information exists with its use during breastfeeding. The consensus opinion is that women taking a statin should not breastfeed because of a concern with disruption of infant lipid metabolism. However, others have argued that children homozygous for familial hypercholesterolemia are treated with statins beginning at 1 year of age, that statins have low oral bioavailability, and risks to the breastfed infant are low, especially with rosuvastatin and pravastatin. Until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.
What if I already have used Pravastatin Sodium | Mckesson Corporation Dba Rx Pak?
We have already established that Pravastatin Sodium | Mckesson Corporation Dba Rx Pak is unsafe in breastfeeding and breastfeeding while using Pravastatin Sodium | Mckesson Corporation Dba Rx Pak is not a good idea however if have already used and then breastfed the baby then you shall monitor the behavior and health of baby closely and inform your doctor as soon as possible. In case of emergency please call 911.
My health care provider has asked me to use Pravastatin Sodium | Mckesson Corporation Dba Rx Pak, what to do?
If your doctor knows that you are breastfeeding mother and still prescribes Pravastatin Sodium | Mckesson Corporation Dba Rx Pak then there must be good reason for that as Pravastatin Sodium | Mckesson Corporation Dba Rx Pak is considered unsafe, It usually happens when doctor finds that overall advantage of taking outweighs the overall risk.
If I am using Pravastatin Sodium | Mckesson Corporation Dba Rx Pak, will my baby need extra monitoring?
Yes, Extra monitoring is required if mother is using Pravastatin Sodium | Mckesson Corporation Dba Rx Pak and breastfeeding as it is considered unsafe for baby.
Who can I talk to if I have questions about usage of Pravastatin Sodium | Mckesson Corporation Dba Rx Pak in breastfeeding?
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week